Cetuximab in combination with methotrexate (MTX) as first-line treatment in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) : A phase Ib randomized phase II study versus single agent MTX
Ham, J.; Meerten, E.; Fiets, E.; Jeurissen Mc Haaglanden, F.; Slingerland, M.; van der Graaf, W.T.A.; van Herpen, C.M.L.; Beerepoot, L.V.
Annals of Oncology Official Journal of the European Society for Medical Oncology 29 Suppl. 8: Viii 381
2018
ISSN/ISBN: 0923-7534
PMID: 32136933
DOI: 10.1093/annonc/mdy287.024
Accession: 069883662
PDF emailed within 0-6 h: $19.90
Related References
Ham, J.C.; van Meerten, E.; Fiets, W.E.; Beerepoot, L.V.; Jeurissen, F.J.F.; Slingerland, M.; Jonker, M.A.; Husson, O.; van der Graaf, W.T.A.; van Herpen, C.M.L. 2020: Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase Ii study Commence Head and Neck 42(5): 828-838Ruzsa, A.; Sen, M.; Evans, M.; Lee, L.W.; Hideghety, K.; Rottey, S.; Klimak, P.; Holeckova, P.; Fayette, J.; Csoszi, T.; Erfan, J.; Forssmann, U.; Goddemeier, T.; Bexon, A.; Nutting, C. 2014: Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) Investigational new Drugs 32(6): 1278-1284
Vermorken, J.B.; Hitt, R.; Geoffrois, L.; Erfan, J.; Kawecki, A.; Zabolotnyy, D.; Schueler, A.; Knecht, R.; Benasso, M.; Kienzer, H. 2007: Cetuximab plus platinum-based therapy first-line in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety results of a randomized phase III trial (EXTREME) EJC Suppls 5(4): 324
Grünwald, V.; Keilholz, U.; Boehm, A.; Guntinas-Lichius, O.; Hennemann, B.; Schmoll, H.J.; Ivanyi, P.; Abbas, M.; Lehmann, U.; Koch, A.; Karch, A.; Zörner, A.; Gauler, T.C. 2015: TEMHEAD: a single-arm multicentre phase Ii study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO) Annals of Oncology: Official Journal of the European Society for Medical Oncology 26(3): 561-567
Brümmendorf, T.; Guigay, J.; Mesía, R.; Trigo, J.; Keilholz, U.; Dittrich, C.; Kerber, A.; Picard, M.; Vermorken, J. 2009: Phase I results from an open-label, randomized, controlled, phase I/Ii study (Advantage) to evaluate the combination of different cilengitide regimens with cisplatin, 5-Fu, and cetuximab in patients with recurrent/metastatic squamous cell cancer of the head and neck (Scchn) European Journal of Cancer Suppls 7(2): 475-476
Fekih, M.; Ferrand, F.R.; Saada, E.; Hamdan, D.; Desmaris, R.; Schilf, A.; Guigay, J. 2011: Poster Efficacy of Cetuximab Alone or in Combination With Docetaxel as Second-line Treatment in Patients With Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (Scchn) European Journal of Cancer 47: S568-S569
Fayette, J.; Lefebvre, G.; Posner, M.R.; Bauman, J.; Salas, S.; Even, C.; Saada-Bouzid, E.; Seiwert, T.; Colevas, D.; Calmels, F.; Zerbib, R.; Boyer Chammard, A.; Cohen, R. 2018: Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) Annals of Oncology: Official Journal of the European Society for Medical Oncology 29 Suppl. 8: Viii 374
Vermorken, J.B.; Mesia, R.; Vega-Villegas, M.E.; Remenar, E.; Hitt, R.; Kawecki, A.; Rottey, S.; Zabolotnyy, D.; Erfan, J.; Amellal, N. 2016: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME) Journal of Clinical Oncology 24(18_Suppl): 5537-5537
Hitt, R.; Irigoyen, A.; Cortes-Funes, H.; Grau, J.J.; García-Sáenz, J.A.; Cruz-Hernandez, J.J. 2012: Phase Ii study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck Annals of Oncology: Official Journal of the European Society for Medical Oncology 23(4): 1016-1022
Bossi, P.; Miceli, R.; Locati, L.D.; Ferrari, D.; Vecchio, S.; Moretti, G.; Denaro, N.; Caponigro, F.; Airoldi, M.; Moro, C.; Vaccher, E.; Sponghini, A.; Caldara, A.; Rinaldi, G.; Ferrau, F.; Nolè, F.; Lo Vullo, S.; Tettamanzi, F.; Hollander, L.; Licitra, L. 2017: A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck Annals of Oncology: Official Journal of the European Society for Medical Oncology 28(11): 2820-2826
Bossi, P.; Miceli, R.; Locati, L.D.; Ferrari, D.; Vecchio, S.; Moretti, G.; Denaro, N.; Caponigro, F.; Airoldi, M.; Moro, C.; Vaccher, E.; Sponghini, A.; Caldara, A.; Rinaldi, G.; Ferrau, F.; Nolè, F.; Lo Vullo, S.; Tettamanzi, F.; Hollander, L.; Licitra, L. 2017: A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck Annals of Oncology: Official Journal of the European Society for Medical Oncology 28(11): 2820-2826
Tahara, M.; Kiyota, N.; Yokota, T.; Hasegawa, Y.; Muro, K.; Takahashi, S.; Onoe, T.; Homma, A.; Taguchi, J.; Suzuki, M.; Minato, K.; Yane, K.; Ueda, S.; Hara, H.; Saijo, K.; Yamanaka, T. 2018: Phase Ii trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02) Annals of Oncology: Official Journal of the European Society for Medical Oncology 29(4): 1004-1009
Chow, L.Q.M.; Eaton, K.D.; Baik, C.; Goulart, B.; Morishima, C.; Disis, M.L.; Manjarrez, K.; Dietsch, G.; Hershberg, R.; Martins, R.G. 2014: Phase 1b Trial of TLR8 Agonist VTX-2337 in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN) International Journal of Radiation Oncology*biology*physics 88(2): 503-504
Machiels, J.-P.; Kaminsky, M.-C.; Keller, U.; Brümmendorf, T.H.; Goddemeier, T.; Forssmann, U.; Delord, J.-P. 2013: Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck Investigational new Drugs 31(5): 1207-1216
Le Tourneau, C.; Ghiani, M.; Cau, M.C.; Depenni, R.; Ronzino, G.; Bonomo, P.; Montesarchio, V.; Leo, L.; Schulten, J.; Messinger, D.; Sbrana, A.; Ghi, M.G. 2018: Cetuximab + platinum-based therapy (PBT) as a first-line treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): An observational study (ENCORE) Annals of Oncology: Official Journal of the European Society for Medical Oncology 29 Suppl. 8: Viii 377